Presbia to Participate in the XXXV Congress of the European Society of Cataract & Refractive Surgeons & in the International ...
October 02 2017 - 8:00AM
Business Wire
Presbia PLC (NASDAQ: LENS), an ophthalmic device company and
leader in near-vision restoration, will participate at the XXXV
Congress of the European Society of Cataract and Refractive
Surgeons (ESCRS), Europe’s leading organization for cataract and
refractive surgeons, to be held in Lisbon, Portugal on October 7th
through 11th.
The Presbia Flexivue Microlens is currently approved for sale in
42 countries around the world. The company is planning to make its
final submission to the FDA before the end of 2017 in anticipation
of approval in 2018. Several surgeons who have implanted the
Presbia Flexivue Microlens commercially and as part of the FDA
study will be sharing their hands-on experience with the product at
ESCRS.
Prof. Tae Young Chung, who is conducting a clinical study with
the Presbia Flexivue Microlens at Samsung Medical Center in South
Korea, will present at the ESCRS congress.
Prof. Pallikaris, who has experience with the Presbia Flexivue
Microlens since 2007, is participating in an Instructional Course
titled “Corneal Inlay Technologies for the Treatment of
Presbyopia”.
On October 5th, Dr. Fantozzi, who first performed the Presbia
Flexivue Microlens procedure over seven years ago, will present
long-term results at the Presbymania event, an event where experts
from around the world gather to discuss the surgical treatment of
presbyopia.
Dr. Karl Stonecipher, a clinical investigator who is
participating in the FDA pivotal study of the Presbia Flexivue
Microlens, will also conduct a presentation at the International
Society of Presbyopia (ISOP) that is being held at the Saba Lisboa
Hotel on October 6th in Lisbon.
Mr. Todd Cooper, President and CEO of Presbia will give a
presentation at the Ophthalmology Futures European Forum, focusing
on the transformation of presbyopia correction with the Presbia
Flexivue Microlens. This will take place on Thursday, October 5th
at the Myriad Crystal Center, Lisbon, Portugal.
“Presbia’s presentations being held at ESCRS and at ISOP will
increase industry leaders’ awareness of the positive results that
have been consistently reported globally by surgeons and patients
using our Microlens as the treatment for near-vision loss,” said
Todd Cooper, President and CEO of Presbia. “Surgeons will have an
opportunity for hands-on experience with our product at the Presbia
booth, enabling them to experience our unique presbyopia
solution.”
Presbia representatives will be available for one-on-one
meetings at booth number P288 during the ESCRS.
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Information provided and statements contained
in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements only
speak as of the date of this press release and Presbia assumes no
obligation to update the information included in this press
release. Statements made in this press release that are
forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk
Factors" in our annual report on Form 10-K and quarterly reports on
Form 10-Q and other reports we file with the Securities and
Exchange Commission. Accordingly, you are cautioned that any such
forward-looking statements are not guarantees and are subject to
certain risks, uncertainties and assumptions that are difficult to
predict. Although Presbia believes that the expectations reflected
in such forward-looking statements are reasonable as of the date
made, expectations may prove to have been materially different from
the results expressed or implied by such forward-looking
statements. Unless otherwise required by law, Presbia also
disclaims any obligation to update its view of any such risks or
uncertainties or to announce publicly the result of any revisions
to the forward-looking statements made in this press release.
About Presbia
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that
has developed and is currently marketing the presbyopia-correcting
Presbia Flexivue Microlens™, a miniature lens that is implanted in
a corneal pocket created by a femtosecond laser. The Presbia
Flexivue Microlens has received a CE mark for the European Economic
Area, allowing the lens to be marketed in over 30 countries across
Europe. A staged pivotal U.S. clinical trial for the Presbia
Flexivue Microlens commenced in 2014.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171002005674/en/
Presbia PLCMonica Yamada,
323-860-4903monica@presbia.com
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2024 to Jul 2024
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2023 to Jul 2024